The role of anti-PD-L1 agents in the adjuvant treatment of early-stage NSCLC has been primarily investigated through the IMpower010 trial (NCT02486718), which evaluated the efficacy of atezolizumab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.